NASDAQ:INVA

Innoviva (INVA) Stock Price, News & Analysis

Innoviva logo
$18.41 +0.01 (+0.05%)
Closing price 04:00 PM Eastern
Extended Trading
$18.77 +0.36 (+1.98%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Innoviva Stock (NASDAQ:INVA)

Advanced

Key Stats

Today's Range
$18.19
▼
$18.56
50-Day Range
$18.30
▼
$21.45
52-Week Range
$18.19
▼
$25.15
Volume
837,536 shs
Average Volume
792,612 shs
Market Capitalization
$1.31 billion
P/E Ratio
9.25
Dividend Yield
N/A
Price Target
$37.00
Consensus Rating
Moderate Buy

Company Overview

Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK.

Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions. Its portfolio includes products such as Xenleta and Xacduro for certain bacterial infections, Xerava for complicated intra-abdominal infections, and Giapreza for dangerously low blood pressure in adults with septic or other distributive shock.

The company was formerly known as Theravance, Inc. and adopted the Innoviva name in 2015, following the separation of Theravance Biopharma. Innoviva’s products and royalty arrangements give it a presence in markets beyond the United States, though the geographic reach varies by product and commercial partner.

AI Generated. May Contain Errors.

Innoviva Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

INVA MarketRank™: 
2.430053227785 of 5 stars

Innoviva scored higher than 49% of companies evaluated by MarketBeat, and ranked 1057th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Innoviva has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Innoviva has a consensus price target of $37.00, representing about 101.0% upside from its current price of $18.41.

  • Amount of Analyst Coverage

    Innoviva has only been the subject of 4 research reports in the past 90 days.

  • Read more about Innoviva's stock forecast and price target.
  • Earnings Growth

    Earnings for Innoviva are expected to decrease by -10.73% in the coming year, from $2.33 to $2.08 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Innoviva is 9.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.67.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Innoviva is 9.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.85.

  • Price to Earnings Growth Ratio

    Innoviva has a PEG Ratio of 2.62. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Innoviva has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.59% of the float of Innoviva has been sold short.
  • Short Interest Ratio / Days to Cover

    Innoviva has a short interest ratio ("days to cover") of 12.88, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Innoviva has recently increased by 3.16%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Innoviva does not currently pay a dividend.

  • Dividend Growth

    Innoviva does not have a long track record of dividend growth.

  • News Sentiment

    Innoviva has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Innoviva this week, compared to 3 articles on an average week.
  • Search Interest

    6 people have searched for INVA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Innoviva insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.01% of the stock of Innoviva is held by insiders.

  • Percentage Held by Institutions

    99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Innoviva's insider trading history.
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INVA Stock News Headlines

HC Wainwright Issues Positive Forecast for Innoviva Earnings
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
HC Wainwright Issues Negative Forecast for Innoviva Earnings
See More Headlines

INVA Stock Analysis - Frequently Asked Questions

Innoviva's stock was trading at $19.99 on January 1st, 2026. Since then, INVA shares have decreased by 7.9% and is now trading at $18.41.

Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Wednesday, November, 4th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.52 by $1.55. The biotechnology company earned $106.12 million during the quarter, compared to analysts' expectations of $115.31 million. Innoviva had a net margin of 44.13% and a trailing twelve-month return on equity of 22.91%.

Top institutional shareholders of Innoviva include State Street Corp (4.84%), Goldman Sachs Group Inc. (2.28%), Royce & Associates LP (1.55%) and William Blair Investment Management LLC (1.15%).
View institutional ownership trends
.

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include NVIDIA (NVDA), Micron Technology (MU), Intel (INTC), Advanced Micro Devices (AMD), Tesla (TSLA), Exelixis (EXEL) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
11/04/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CIK
1080014
Employees
159
Year Founded
1996

Price Target and Rating

High Price Target
$46.00
Low Price Target
$29.00
Potential Upside/Downside
+101.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.99
Trailing P/E Ratio
9.25
Forward P/E Ratio
8.85
P/E Growth
2.62
Net Income
$271.17 million
Net Margins
44.13%
Pretax Margin
51.10%
Return on Equity
22.91%
Return on Assets
16.67%

Debt

Debt-to-Equity Ratio
0.23
Current Ratio
15.44
Quick Ratio
14.58

Sales & Book Value

Annual Sales
$438.32 million
Price / Sales
2.99
Cash Flow
$5.06 per share
Price / Cash Flow
3.64
Book Value
$16.00 per share
Price / Book
1.15

Miscellaneous

Outstanding Shares
71,081,000
Free Float
69,652,000
Market Cap
$1.31 billion
Optionable
Optionable
Beta
0.38

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:INVA) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners